Navigation Links
Quantel Signs a Distribution Agreement With US-based National Biological

LES ULIS, France, October 14 /PRNewswire-FirstCall/ --

- National Biological to Market Quantel`s 308 Excimer System for Psoriasis and Vitiligo in the United States

Quantel SA (Euronext: QUA), a leading manufacturer of solid state lasers, announced today that it has entered into a Distribution Agreement with National Biological, a leading researcher and developer of light-based systems for medical and cosmetic treatments, for Quantel's 308 Excimer System for monochromatic UVB treatment of psoriasis and vitiligo in the United States.

Monochromatic UVB Therapy

The 308 Excimer System was developed by Quantel Derma, GmbH based in Erlangen, Germany. Its monochromatic light is equivalent to an excimer laser, with comparable clinical results. The 308 Excimer System is portable, efficient and has no consumables.

National Biological's Chief Executive Officer, Ken Oif commented, "The Quantel 308 targeted phototherapy System provides the best solution for the tens of thousands of patients who require localized treatment for psoriasis, vitiligo, and other skin diseases which are responsive to UV light. It is proven to be very effective and extremely easy to use. National Biological is very pleased to be able to provide Dermatologists with the best value of any targeted phototherapy system."

Exclusivity in the United States

The 308 Excimer System will be exclusively marketed by National Biological in the United States. National Biological will provide the Marketing, Sales, Clinical and Service support.

Alain de Salaberry, Quantel's Président Directeur Général said: "Its strong sales organization and its experience with UVB devices make National Biological an ideal partner for the marketing of Quantel's 308 Excimer System."


Founded in 1970, the QUANTEL Group has over the last 10 years established itself as one of the world's leading specialists for scientific (research laboratories, universities), industrial (micromachining, metrics, military) and medical (ophthalmology, dermatology) laser technologies.

ABOUT Nation Biological Corporation, Inc.

National Biological was founded in 1967 by a pharmacist who understood clearly that UV phototherapy provided a safer and more effective treatment than drugs for severe or chronic psoriasis, eczema, vitiligo and other skin conditions. Over the nearly 40 years since then, National Biological has become widely recognized among doctors and patients alike as the world leader in our field, consistently providing innovation, manufacture, and distribution of phototherapy equipment.

    Quantel is listed on NYSE Euronext (compartiment C) FR0000038242 - QUA

    Alain de SALABERRY
    Président Directeur Général
    T : +33-1-69-29-17-00

    Stefan SCHULZE
    CEO Quantel Derma GmbH
    T : +49-9131-9408810

    Mark Friedman
    T : +1-216-831-0600


Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
2. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
3. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
4. Monsanto Company Signs Share Subscription Agreement With Devgen
5. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
6. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
7. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
8. Assay Designs(TM) Announces Additions to the Leadership Team
9. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
10. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
11. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... ... Market with the addition of its newest module, US Hemostats & Sealants. , ... thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... launched Rosalind™, the first-ever genomics analysis platform specifically designed for life science ... in honor of pioneering researcher Rosalind Franklin, who made a major contribution ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
Breaking Biology Technology:
(Date:8/15/2017)... 2017   ivWatch LLC , a medical device company focused ... announced receipt of its ISO 13485 Certification, the global standard for ... for Standardization (ISO®). ... 400 Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, ...
(Date:6/30/2017)... , June 30, 2017 Today, American ... and supplier of face and eye tracking software, ... Product provider program. "Artificial intelligence ... way to monitor a driver,s attentiveness levels while ... being able to detect fatigue and prevent potential ...
(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
Breaking Biology News(10 mins):